NEWS

NEWS

Total 86

36
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
2021-03-23
35
Press Release NeoImmuneTech Announces Closing of Initial Public Offering
2021-03-16
34
Press Release NeoImmuneTech Appoints Byung Ha Lee, Ph.D., as Chief Scientific Officer
2021-03-01
33
Press Release NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
2021-02-23
32
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2021-02-16
31
Press Release NeoImmuneTech Receives Notice of Approval from the Korea Exchange for Initial Public Offering on the KOSDAQ
2020-12-30
30
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 1 Study of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19
2020-11-30
29
Press Release NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer
2020-11-16
28
Press Release NeoImmuneTech to Present at Upcoming Scientific/Medical Conferences
2020-11-10
27
Press Release Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-negative Breast Cancer
2020-11-10

<<<6 7 8 9